Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review
Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). We searched ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform. A variety of antithrombotic agents, doses, and duration of therapy are being assessed in ongoing randomized controlled trials. Table 1 summarizes study-level inclusion and exclusion.

Related Post